Stock listing
A41038 Stock Price, News, Filings & Events — Biolinerx Ltd.
Selected listing: A41038 · LS · EUR · DE
This page tracks Biolinerx Ltd.'s A41038:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A41038:LS. A41038:LS is the stock-level entry point for investors researching Biolinerx Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A41038:LS
- Asset type
- Stock
- Market cap
- $13.2M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS
- Currency
- EUR
Biolinerx Ltd. A41038:LS stock context
This page tracks Biolinerx Ltd.'s A41038:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A41038:LS. A41038:LS is the stock-level entry point for investors researching Biolinerx Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Biolinerx Ltd.
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 27, 2026
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
May 20, 2026
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
April 28, 2026
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
April 8, 2026
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
March 26, 2026
Biolinerx Ltd. earnings calls
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call
August 31, 2026 · Upcoming call
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call
May 27, 2026 · Replay with transcript and chapters
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call
March 23, 2026 · Replay with transcript and chapters
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call
November 24, 2025 · Replay with transcript and chapters
BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call
August 14, 2025 · Replay with transcript and chapters
BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call
May 27, 2025 · Replay with transcript and chapters
Research Biolinerx Ltd.
Biolinerx Ltd. investor report
Review AI stock analysis and investor report context for A41038:LS.
Biolinerx Ltd. company profile
View the public company page for Biolinerx Ltd. on 6ix.
Biolinerx Ltd. news
Read company news and market updates connected to Biolinerx Ltd..
Biolinerx Ltd. investor events
Find investor webinars, events, and replay context for Biolinerx Ltd..
Alternate listings
BLRX:TASE
IL · ILA
Alternate listing for Biolinerx Ltd.; the primary context on this page is A41038:LS.
BLRX:NASDAQ
US · USD
Alternate listing for Biolinerx Ltd.; the primary context on this page is A41038:LS.
BLRX:BOATS
US · USD
Alternate listing for Biolinerx Ltd.; the primary context on this page is A41038:LS.
YP2:FWB
DE · EUR
Alternate listing for Biolinerx Ltd.; the primary context on this page is A41038:LS.
YP2:GETTEX
DE · EUR
Alternate listing for Biolinerx Ltd.; the primary context on this page is A41038:LS.
YP2:MUN
DE · EUR
Alternate listing for Biolinerx Ltd.; the primary context on this page is A41038:LS.
YP2:SWB
DE · EUR
Alternate listing for Biolinerx Ltd.; the primary context on this page is A41038:LS.